Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. NC4007649

AURORA BIOLABS LLC PD-1/PD-L1 Inhibitor Binding Assay Kit,384 rxn

Catalog No. NC4007649
Encompass_Preferred

Immune checkpoint blockade is an important cancer immunotherapy strategy that enhances the immune system’s ability to recognize and destroy tumor cells. The PD-1/PD-L1 signaling pathway is a key immune checkpoint that suppresses T-cell activity and allows cancer cells to evade immune surveillance. Blocking the interaction between PD-1 and PD-L1 can restore immune function and improve anti-tumor responses. The PD-1/PD-L1 Inhibitor Binding Assay is a TR-FRET–based assay designed to quantitatively measure the interaction between PD-1 and PD-L1. In this assay, binding of PD-1 to PD-L1 generates a fluorescence resonance energy transfer (FRET) signal that can be detected by measuring fluorescence emission at 665 nm and 620 nm. Compounds or antibodies that inhibit PD-1/PD-L1 binding reduce the TR-FRET signal, enabling evaluation of potential immune checkpoint inhibitors for cancer research and drug discovery applications.

Catalog No. NC4007649 Supplier AURORA BIOLABS LLC Supplier No. 237352384
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Immune checkpoint blockade is an important cancer immunotherapy strategy that enhances the immune system’s ability to recognize and destroy tumor cells. The PD-1/PD-L1 signaling pathway is a key immune checkpoint that suppresses T-cell activity and allows cancer cells to evade immune surveillance. Blocking the interaction between PD-1 and PD-L1 can restore immune function and improve anti-tumor responses. The PD-1/PD-L1 Inhibitor Binding Assay is a TR-FRET–based assay designed to quantitatively measure the interaction between PD-1 and PD-L1. In this assay, binding of PD-1 to PD-L1 generates a fluorescence resonance energy transfer (FRET) signal that can be detected by measuring fluorescence emission at 665 nm and 620 nm. Compounds or antibodies that inhibit PD-1/PD-L1 binding reduce the TR-FRET signal, enabling evaluation of potential immune checkpoint inhibitors for cancer research and drug discovery applications.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.